Gene profiling of SEC13, SMAD7, GHRL, long non-coding RNA GHRLOS, HIF-1α in gastric cancer patients

Neveen A. Hussein1, Mona M. Rashad1, Azza S. Abdou2, Amr M. Hussein3 & Hagar M. Mohamed1

Even with considerable progress in cancer researches, gastric cancer is still one of the global health problems. Recognition of the differential expressed genes in GC is the most appropriate approach for establishing new diagnostic targets. This study evaluates SEC13, SMAD7, GHRL, IncRNA GHRLOS, HIF-1α genes profiling as well as HIF-1α protein level for GC. The expression of selected genes, serum HIF-1α and CEA protein levels were determined for 50 GC patients and 50 healthy controls by real-time RT-PCR, ELISA, and ELICA respectively. The sensitivities of these parameters as diagnostic biomarkers were evaluated. SMAD7, HIF-1α expression, serum HIF-1α, and CEA level were significantly upregulated in GC patients as compared to the control group (P = 0.024, < 0.001) and had significant positive correlations between each other except SMAD7 with serum HIF-1α, and CEA level. On the other hand, SEC13, GHRL, and IncRNA GHRLOS expression were significantly downregulated in GC patients (P = < 0.001, 0.025, < 0.001 respectively) and had significant positive correlations with each other (P < 0.001). Significant negative correlations were observed between most of both groups. All studied parameters were associated with GC clinical stages except SMAD7 was associated with stage IV only (P = 0.005) and GHRL did not associate with tumor stages (P > 0.05). All studied parameters may be promising biomarkers for the early diagnosis of GC. SMAD7, HIF-1α gene, and HIF-1α protein may be jointly implicated in cancer development and prognosis, while SEC13, GHRL, and IncRNA GHRLOS may act as tumor suppressors.

Globally, gastric cancer (GC) is still a significant cancer that is responsible for more than one million new cases in 2020 (nearly 1,089,103) and 769,000 deaths (one in every 13 deaths). Moreover, it is 5th for incidence (5.6%) and 4th for mortality (7.7%). The rate of GC in men is two-fold higher than in females. In Egypt, GC is 10th cause of cancer with incidence and mortality rates 3.353 (2.5%) and 2.631 (3.0%) respectively1. The high mortality rate of GC may be due to the lack of diagnostic and prognostic markers. Also, the molecular mechanisms responsible for GC are still need realization. So, novel reliable biomarkers are urgently required for early diagnosis. Genes profiling become an attractive focus of research.

Transforming growth factor-β (TGF-β) pathway is multifunctional cytokines which have various impacts on controlling of cell fate throughout embryonic growth and homeostasis of adult tissue. Aberrant TGF-β signaling may cause diseases, including cancer2. The canonical TGF-β signaling pathway is through SMAD proteins where its downstream events involve formation of SMAD2 or 3 complexes with SMAD4, translocated to nucleus and subsequent stimulation of target genes. Without ligand, the inhibitory SMADs (SMAD6 and SMAD7) are located mainly in the nucleus. By activation of TGF-β receptor, the inhibitory SMADs accumulate in the cytoplasm and associate with the activated receptor, provoking TGF-β signaling3.

SEC13 is a component of the endoplasmic reticulum and the nuclear pore complex (NPC) and is thought to function as scaffold to NPC. Additionally, the nucleoporin SEC13 is associated with chromatin and directly has an important role in transcriptional regulations4.

1Applied Medical Chemistry Department, Medical Research Institute, Alexandria University, Alexandria, Egypt. 2Human Physiology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt. 3Cancer Management and Research Department, Medical Research Institute, Alexandria University, Alexandria, Egypt. *email: neveen.hussien@alexu.edu.eg
SMADs genes encode transcriptional modulators and signal transducers that mediate several signaling pathways like Wnt/β-catenin, Hippo and TGF-β. SMAD7 gene (small mothers against decapentaplegic) is induced by TGF-β that encodes for negative regulators of TGF-β/SMAD pathway. SMAD7 may antagonize TGF-β signaling in nucleus via interrupting a formation of SMAD-DNA complex. Furthermore, SMAD7 recruits E3 ubiquitin ligases (SMAD ubiquitination regulatory factor 1/2), and thus supports its ubiquitination-mediated proteasomal and/or lysosomal degradation.

Ghrelin gene (GHRL) translates for 28-amino acid peptide hormone (ghrelin) which was initially purified from the stomach mucosa and acts as a ligand for growth hormone secretagogue receptor. Ghrelin is a vital player in different biological processes, involving fat metabolism, growth hormone release, immune system and gut motility.

LncRNA is a group of non-protein coding RNAs exceeding 200 nucleotides and according to its biological positions and roles can categorized into sense, antisense, intergenic, and intronic LncRNA. Most LncRNAs are controlling transcriptional and post-transcriptional levels like mRNA and protein stability, gene splicing, and nuclear cytoplasm exporting levels. GHRLOS (Ghrelin Gene Opposite Strand) is the natural antisense transcript and exhibit numerous unique characteristics of non-coding genes as extensive splicing, 5′ capping, short open reading frames, and polyadenylation.

Hypoxia-inducible factors (HIF-1α, -2α, -3α, -1β) are critical transcriptional regulator of cell response to hypoxia where they involved in immunity, energy metabolism, microbial homeostasis and renewal. HIF-1α is a prospective target gene implicated in bioenergetic metabolism including upregulate glucose transporters (GLUT1, GLUT4 and GLUT8), the genes expression of glycolysis enzyme, and lactate dehydrogenase-5 (LDH-5). The produced lactate by LDH is circulated, acidifying the cellular matrix and could additional prompt aggressive behavior.

Therefore, this study aimed to evaluate the expression of SEC13, SMAD7, GHRL, LncRNA GHRLOS, HIF-1α genes as well as HIF-1α protein level as diagnostic biomarkers for GC. Correlations of these parameters with clinicopathological characteristics of GC patients were also estimated.

Subjects and methods

The study was conducted on 50 newly diagnosed GC patients (age range, 44–69 years; median 50 years) who were selected from those admitted to Medical Research Institute, Cancer Management and Research Department, Alexandria University and 50 healthy volunteers (control group, age range, 40–65 years; median 48 years).

Patients underwent gastroscopy and diagnosed pathologically GC were included in this study while patients who received surgical resection or adjuvant chemotherapy and/or radiotherapy or had a history of other malignant disease were excluded.

The study has been approved by the Ethics Committee of Medical Research Institute, Alexandria University and according with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for human study. Assigned informed consent was obtained from all the participants.

Blood sampling. Fasting blood (6 ml) was withdrawn from each participant, patients before surgery and controls. In K$_2$EDTA-containing tube, 3 ml blood was pipetted for quantification of SEC13, SMAD7, GHRL, LncRNA GHRLOS, and HIF-1α genes by real time PCR. The remaining blood (3 ml) was collected in tube without anticoagulant, kept at room temperature and then centrifuged 10 min at 6000 rpm. Sera have been utilized for quantification of HIF-1α and CEA protein by ELISA and ELICA respectively.

Relative quantification of SEC13, SMAD7, GHRL, LncRNA GHRLOS, and HIF-1α genes. Total RNA was extracted and purified by QIAamp RNA Mini kit (Qiagen, USA). For each sample, the absorbance at 260 nm and A260/A280 ratio were measured to assess the RNA concentration and purity respectively (Nanodrop spectrophotometer, Thermo Fisher Scientific 2000, USA). High-Capacity cDNA Reverse Transcription Kits were used to synthesize cDNA (Applied Biosystems, USA).

Real time PCR. Amplification reaction of these genes was performed in 25 µl using SYBR Green Master Mix containing dNTPs, buffer, SYBR Green dye, and thermostable hot-start DNA polymerase (Thermo Fisher Scientific Inc.). The PCR conditions were 95°C for 15 min followed by 40 cycles at 94°C for 15 s and 70°C for 60 s. The genes relative quantification was normalized to GAPDH (endogenous control) and calculated using $2^{-\Delta\Delta CT}$ method.

SEC13-Hs01115007_m1, #4448892 (Invitrogen- Life Technologies-Thermo Fisher Scientific Inc, USA).
Serum HIF-1α and CEA. The HIF-1α protein (ng/ml) was measured by ELISA kit (Monobind Inc, USA). The concentration of each sample was calculated from the standard curve (500 ng/ml). The CEA level (ng/ml) was performed by electro chemiluminescence immunoassay (ELICA, Roche Diagnostics Gmbh, Germany) using Cobase 411 immunoassay analyzer.

Statistical analysis. Data were analyzed by utilizing the IBM SPSS version 20.0. Significance at \( P < 0.05 \). Chi-square test, for categorical variables, to compare between different groups. The abnormally distributed quantitative variables, Kruskal Wallis and Mann Whitney tests were used. For normally distribution, comparing between two studied groups was done by Student t-test. Spearman coefficient was used for correlation. Receiver operating characteristic curve (ROC) was applied to compare the diagnostic values of studied parameters depending upon the area under the curve (AUC). Elevated AUC relates to a better diagnostic test.

Results
Clinicopathological characteristics. Table 1 revealed that 4 patients were less than 50 years while 46 were above 50 years. For sex, 23 were females, while 27 were males. According to staging of GC patients, 5 were of stage II, 17 were of stage III, and 28 were of stage IV. For histological grading, 13 patients had grade II and 37 had grade III. For tumor size, 33 patients were > 5 cm and 17 were < 5 cm. Concerning CEA level, 9 patients had normal level while 41 had elevated level. Regarding the metastatic state, 30 of them had metastasis to liver while 20 did not. Depending on the family history, 35 of them had a family history while 15 did not. Finally, with respect to the pathological Lauren classification, 5 patients were intestinal while 45 of them were diffused type.

Molecular and biochemical parameters. Statistical analysis of these results revealed that SMAD7, HIF-1α expression, serum HIF-1α and CEA level were significantly upregulated in GC patients as compared to control group \((P=0.024, <0.001, <0.001, <0.001)\) and had significant positive correlations between each other except SMAD7 with serum HIF-1α \((r_s=0.177, P=0.078)\), and CEA level \((r_s=0.169, P=0.093)\). On the other hand, SEC13, GHRL and lncRNA GHRLOS expression were significantly downregulated in GC patients as compared to control group \((P= <0.001, 0.025, <0.001 \text{ respectively})\) and had significant positive correlations with each other \((r_s=0.378, 0.672, 0.397 \text{ respectively, } P <0.001)\). Significant negative correlations were observed.
between most of both groups ($r_s = -0.2, P = 0.046$), ($r_s = -0.258, P = 0.015$), ($r_s = -0.248, P = 0.013$), ($r_s = -0.418, r_s = -0.644, r_s = -0.473, r_s = -0.715, P < 0.001$) (Tables 2, 3).

All studied parameters were associated with GC clinical stages, as their relative median values upregulated with stages (II, III, IV) except SMAD7 was associated with stage IV only and GHRL did not associate with tumor stages (Table 4, Fig. 1).

There were no correlations between all studied parameters and clinicopathological characteristics (age, grade, tumor size, metastatic state, family history and Lauren classification) of GC patients except a significant positive correlation of SMAD7 with tumor size and metastatic state ($P = 0.008, 0.007$ respectively) and a significant negative correlation of SEC13 with family history ($P = 0.033$).

As shown in Table 5 Fig. 2; AUC values were significant high for all parameters SEC13, SMAD7, GHRL, lncRNA GHRLOS, HIF-1α genes, HIF-1α and CEA protein (81.6%, 63.1%, 63%, 96.8%, 72.4%, 100%, 96.1% respectively). SEC13 had 80% sensitivity, 72% specificity, and cut-off ≤ 0.389. SMAD7 had 70% sensitivity, 62% specificity and cut-off > 0.752. GHRL had 60% sensitivity, 58% specificity, and cut-off ≤ 0.39. LncRNA GHRLOS had 90% sensitivity, 98% specificity, and cut-off ≤ 0.03. HIF-1α expression had 84% sensitivity, 68% specificity, and cut-off > 0.895. Serum HIF-1α protein had 100% sensitivity, 100% specificity, and cut-off > 2.18. Finally, serum CEA had 92% sensitivity, 90% specificity, and cut-off > 3.98.

### Discussion

Even with considerable progress in cancer researches, GC is still one of the global health problems. Genes profiling is the most appropriate approaches for establishing new diagnostic biomarkers.

The present results revealed significant down regulation of SEC13 and up regulation of SMAD7 expression in GC patients group as compared to control group. In normal and premalignant cells, TGF-β mainly functions as a tumor suppressor through promoting apoptosis, maintaining genome stability, and reducing proliferation. While cancer cells could evade TGF-β suppression effect; they use TGF-β advertising functions to acquire a growth benefit and undergo processes, like epithelial-mesenchymal transition, which facilitate their invasion, and migration.

Under well oxygenated conditions, SMAD7 is an effective inhibitor of cancer invasion. Hypoxia, which is commonly met in solid tumors, activates SMAD7 expression in HIF- and von Hippel-Lindau protein-dependent manner. The upregulated SMAD7 expression in tumors is correlated with hypoxic gene expression where hypoxia might convert SMAD7 from invasion inhibitor to activator. Hypoxia triggers posttranslational covalent protein alterations (hydroxylation, and phosphorylation). Provoking or preventing these alterations, hypoxia might favor further formation of permanent R-SMAD/SMAD7 complexes and SMAD7 could dephosphorylate R-SMADs then, impact SMAD-stimulated transcription. Moreover, HIF is well-known to bind SMAD3 and changes the activation of hypoxic gene. On the contrary, it would be reasonable that HIF might modify R-SMAD-SMAD4-SMAD7 complex binding to DNA. Additionally, hypoxia has been recognized to stimulate a great number of

### Table 2

| Parameter            | Control (n = 50) | Gastric cancer patients (n = 50) | P       |
|----------------------|-----------------|---------------------------------|---------|
| SEC13 gene           | 4.50 ± 12.12    | 0.34 ± 0.42                     | <0.001* |
| GHRL gene            | 4.87 ± 7.48     | 1.32 ± 3.40                     | 0.025*  |
| SMAD7 gene           | 4.48 ± 8.60     | 5.36 ± 12.04                    | 0.024*  |
| HIF-1α gene          | 3.81 ± 6.56     | 5.60 ± 6.40                     | <0.001* |
| HIF-1α protein       | 17.64 ± 4.12    | 191.6 ± 43.94                   | <0.001* |
| CEA protein          | 2.93 ± 1.01     | 71.77 ± 45.91                   | <0.001* |
| LncRNA GHRLOS        | 3.28 ± 7.84     | 0.11 ± 0.52                     | <0.001* |
| GHRL gene            | 4.87 ± 7.48     | 1.32 ± 3.40                     | 0.025*  |
| SMAD7 gene           | 4.48 ± 8.60     | 5.36 ± 12.04                    | 0.024*  |
| HIF-1α gene          | 3.81 ± 6.56     | 5.60 ± 6.40                     | <0.001* |
| HIF-1α protein       | 17.64 ± 4.12    | 191.6 ± 43.94                   | <0.001* |
| CEA protein          | 2.93 ± 1.01     | 71.77 ± 45.91                   | <0.001* |
| lncRNA GHRLOS        | 3.28 ± 7.84     | 0.11 ± 0.52                     | <0.001* |
| GHRL gene            | 4.87 ± 7.48     | 1.32 ± 3.40                     | 0.025*  |
| SMAD7 gene           | 4.48 ± 8.60     | 5.36 ± 12.04                    | 0.024*  |
| HIF-1α gene          | 3.81 ± 6.56     | 5.60 ± 6.40                     | <0.001* |
| HIF-1α protein       | 17.64 ± 4.12    | 191.6 ± 43.94                   | <0.001* |
| CEA protein          | 2.93 ± 1.01     | 71.77 ± 45.91                   | <0.001* |
| lncRNA GHRLOS        | 3.28 ± 7.84     | 0.11 ± 0.52                     | <0.001* |
| GHRL gene            | 4.87 ± 7.48     | 1.32 ± 3.40                     | 0.025*  |
| SMAD7 gene           | 4.48 ± 8.60     | 5.36 ± 12.04                    | 0.024*  |
| HIF-1α gene          | 3.81 ± 6.56     | 5.60 ± 6.40                     | <0.001* |
| HIF-1α protein       | 17.64 ± 4.12    | 191.6 ± 43.94                   | <0.001* |
| CEA protein          | 2.93 ± 1.01     | 71.77 ± 45.91                   | <0.001* |
| lncRNA GHRLOS        | 3.28 ± 7.84     | 0.11 ± 0.52                     | <0.001* |
| GHRL gene            | 4.87 ± 7.48     | 1.32 ± 3.40                     | 0.025*  |
| SMAD7 gene           | 4.48 ± 8.60     | 5.36 ± 12.04                    | 0.024*  |
| HIF-1α gene          | 3.81 ± 6.56     | 5.60 ± 6.40                     | <0.001* |
| HIF-1α protein       | 17.64 ± 4.12    | 191.6 ± 43.94                   | <0.001* |
| CEA protein          | 2.93 ± 1.01     | 71.77 ± 45.91                   | <0.001* |
genes, so hypoxia-caused alterations in gene expression might change responses of TGF-β to support instead of prevent invasion. SMADs access to their genes is exactly signal dependent, causing SMAD nuclear translocation an important step in TGF-β signal transduction into nucleus. SEC13 has specific properties for SMADs, where SEC13 can provide mechanism by which TGF-β accelerates nuclear import rate of SMADs. Furthermore, SEC13 participates in

Table 3. Correlation between SEC13, GHRL, lncRNA GHRLOS, SMAD7, HIF-1α genes expression, serum HIF-1α and CEA levels in gastric cancer patients’ group. r_s: Spearman coefficient.

Table 4. SEC13, GHRL, lncRNA GHRLOS, SMAD7, HIF-1α genes expression, serum HIF-1α and CEA levels in control and gastric cancer patients’ groups with different stages. P: P value for comparing between all groups utilizing Kruskal Wallis test, pairwise comparison between each two groups was performed by Post Hoc Test. *Significance at P ≤ 0.05.
Figure 1. SEC13, GHRL, lncRNA GHRLOS, SMAD7, HIF-1a expression, serum HIF-1α (ng/ml) and CEA levels (ng/ml) in control and gastric cancer patient groups with different stage.

Table 5. Diagnostic accuracy of SEC13, GHRL, lncRNA GHRLOS, SMAD7, HIF-1α genes expression, serum HIF-1α and CEA levels.

|                  | AUC   | Cut off | Sensitivity | Specificity | 95% CI  | PPV   | NPV   | Accuracy | P       |
|------------------|-------|---------|-------------|-------------|---------|-------|-------|----------|---------|
| SEC13            | 0.816 | ≤ 0.389 | 80.0        | 72.0        | 0.734–0.898 | 74.1  | 78.3  | 76.0     | < 0.001*|
| GHRL             | 0.630 | ≤ 0.390 | 60.0        | 58.0        | 0.521–0.739 | 58.8  | 59.2  | 59.0     | 0.026*  |
| LncRNA GHRLOS    | 0.968 | ≤ 0.030 | 90.0        | 98.0        | 0.930–1.000 | 97.8  | 90.7  | 94.0     | < 0.001*|
| SMAD7            | 0.631 | > 0.752 | 70.0        | 62.0        | 0.518–0.743 | 64.8  | 67.4  | 66.0     | 0.024*  |
| HIF-1α           | 0.724 | > 0.895 | 84.0        | 68.0        | 0.617–0.831 | 72.4  | 81.0  | 76.0     | < 0.001*|
| HIF-1α protein   | 1.000 | > 2.180 | 100.0       | 100.0       | 1.000–1.000 | 100.0 | 100.0 | 100.0    | < 0.001*|
| CEA protein      | 0.961 | > 3.980 | 92.0        | 90.0        | 0.926–0.996 | 90.2  | 91.8  | 91.0     | < 0.001*|

CI: Confidence intervals, AUC: area under the curve, PPV: positive predictive value, NPV: negative predictive value. *Statistically significant at \( P \leq 0.05 \). #Cut off was choose according to Youden index.
According to SEC13 functions, the significant down regulation of SEC13 expression in GC patients may be one of the factors that leads to TGF-β signaling aberrant. This study confirmed decrease in SEC13 expression with all cancer stages (II, III, IV); while SMAD7 tended to be especially highly expressed in GC patients with stage IV, which could explain the significant negative correlation between SEC13 and SMAD7.

The present study revealed down expression of GHRL in GC patients as compared to control group. Also, GHRL expression was not associated with GC stages. This result agreed with Pritchett et al., 2020 and Hu et al., 202121,22. Ghrelin has anti-inflammatory effects where it alleviates production of nuclear factor-κB and pro-inflammatory cytokines. Additionally, GHRL suppress macrophage-produced inflammatory cytokines and cyclooxygenase-2 expression23. GHRL activates gastric vagus nerve which delivers the gastrointestinal tract immune information to the hypothalamus24. Therefore, ghrelin’s anti-inflammatory impacts may protect against tumorigenesis25.

AMP-activated protein kinase (AMPK) is the master sensor of cell energy level and it has been proven to control the cell critical functions, involving growth and metabolism, and constantly could be implicated in initiation and development of tumor26. Also, AMPK is a negative regulator of Warburg effect to suppress of GC development27. A recent study by Hu et al. 202122 recognized that overexpression of GHRL may inhibit GC cell proliferation, invasion, and support apoptosis by activating AMPK pathway. GHRL knockdown enhanced uptake of glucose and release of lactic acid, indicating that GHRL provoked the anti-Warburg effect through AMPK signaling pathway to prevent GC. Accordingly, the observed decrease in GHRL expression in GC patients led to assume that GHRL may function as the tumor suppressor.

The present results showed a significant down regulation in lncRNA GHRLOS in GC patients group as compared to control group. As well as a significant association with GC stages (II, III, IV). These findings are consistent with other research which proved that lncRNA GHRLOS may act as a tumor suppressor during colorectal carcinogenesis and its down regulation stimulates CRC progression28 through its functional and regulatory roles in ghrelin axis12.

In cancer cells the main feature in response to hypoxia is induction of HIF-1α as well as its downstream target to enhance blood vessel formation, and aggression32. Reactive oxygen species (ROS) induce HIF-1α transcriptional activity through stimulation of NF-κB, extracellular signal-regulated kinases (ERK1/2) and PI3K/ Akt/m-TOR pathways. Reactive nitrogen species (RNS) induce S-nitrosation of prolyl 4-hydroxylase 2 (PHD2) to
elevate HIF-1α stability and activity\(^\text{14,33}\). In addition to oxygen, HIF-1 may be regulated by other stimuli involving hormones (insulin), growth factors (platelet-derived growth factor) and vasoactive peptide (angiotensin-2)\(^\text{34}\). The present study demonstrated that a significant elevation in CEA in GC patients that trends to be significantly increased with GC clinical stages as compared to control group. The secretion and transcription of CEA are controlled by TGF-β pathway and SMAD3-facilitated tumor growth factor\(^\text{35}\). Hypoxia increases CEA protein level and its promoter activity directly through HIF-1α binding\(^\text{36}\) and indirectly through increase cellular pH by activation of plasma membrane Na\(^+\)/H\(^+\) exchanger\(^\text{37}\). Previous study has revealed that E-box represents an important site for the total activity of CEA promoter and contain potential binding sites for various transcription factors as HIF-1α\(^\text{38}\).

The correlations of all studied parameters with clinicopathological characteristics of GC patients showed some variation than other previous studies\(^\text{19,40}\) and this may be due to difference in sample numbers and methods used. The observed correlations between all studied parameters are reasoning since under hypoxia condition TGF-β/SMAD signaling is promoted. TGF-β upregulates HIF-1α expression and induces HIF-1α DNA binding activity. TGF-β affects HIF-1α activity and accumulation via enhancing stability of HIF-1α protein\(^\text{41}\). Besides, HIF-1α plays a main role for the elevation of CEA protein level and promotes its activity\(^\text{36}\). Furthermore, SMAD7 is activated by hypoxia in HIF- and VHL-dependent manner and its inhibitory effect on invasion is totally lost\(^\text{39}\). Also, with hypoxic condition, GHRL reduces the level of HIF-1α\(^\text{42}\). Additionally, lncRNAs can act as a direct or indirect regulator of HIFs and can improve or reduce its function in cancer\(^\text{43}\). lncRNA GHRLOS is positively correlated with GHRL and negatively correlated with HIF-1α protein. So that, lncRNA GHRLOS may exert the same inhibitory effect.

The present results indicated that the validity of using SEC13, SMAD7, GHRL, IncRNA GHRLOS, HIF-1α genes, and HIF-1α protein as diagnostic markers for GC. Additionally, HIF-1α protein was superior to lncRNA GHRLOS followed by CEA protein, SEC13, HIF-1α, SMAD7, and GHRL genes for GC diagnosis.

Conclusion: SEC13, SMAD7, GHRL, IncRNA GHRLOS, HIF-1α genes, and HIF-1α protein may be considered as promising biomarkers for the early detection of gastric cancer. SMAD7, HIF-1α gene and HIF-1α protein may be jointly involved in tumor development and prognosis (act as oncogenic factors), while SEC13, GHRL, and IncRNA GHRLOS may act as tumor suppressor factors and thus could be considered as novel therapeutic targets for gastric cancer.

Data availability
All data generated or analyzed during this study are included in this published article.

Received: 18 February 2022; Accepted: 29 March 2022
Published online: 21 April 2022

References
1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J. Clin. 71, 1–41 (2021).
2. Lui, S., Ren, J. & Ten Dijke, P. Targeting TGFβ signal transduction for cancer therapy. Signal Transduct. Target Ther. 6, 8 (2021).
3. Kim, Y. H. et al. Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. Ann. Oncol. 15, 574–580 (2004).
4. Capelson, M. et al. Chromatin-bound nuclear pore components regulate gene expression in higher eukaryotes. Cell 140, 372–383 (2010).
5. Budi, E. H., Duan, D. & Derynck, R. Transforming growth factor- receptors and smads: Regulatory complexity and functional versatility. Trends Cell Biol. 27, 658–672 (2017).
6. De Cuninck, V. C. C., Split, M. & Ten, D. P. Current prospective on inhibitory SMAD7 in health and disease. Crit. Rev. Biochem. Mol. Biol. 55, 691–715 (2020).
7. Shi, X. et al. Study the interaction between Smad7 and DNA by signal-molecule force spectroscopy. Biochem. Biophys. Res. Commun. 377, 1284–1287 (2008).
8. Kuratomi, G. et al. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4–2) negatively regulates TGF-β (transforming growth factor-β) signaling by inducing ubiquitin-mediated degradation of Smad2 and TGF-β-type I receptor. Biochem. J. 386, 461–470 (2005).
9. Gray, S. M., Page, L. C. & Tong, J. Ghrelin regulation of glucose metabolism. J. Neuroendocrinol. 31, e12705 (2019).
10. Ma, L., Bajic, V. B. & Zhang, Z. On the classification of long non-coding RNAs. Mol. Cells. 55, 27–36 (2018).
11. He, R. Z., Luo, D. X. & Mo, Y. Y. Emerging roles of lncRNA in the post transcriptional regulation in cancer. Genes Dis. 6, 6–15 (2019).
12. Seim, I. et al. Complex organization and structure of the ghrelin antisense strand gene GHRLOS, a candidate non-coding RNA gene. BMC Mol. Biol. 9, 95–117 (2008).
13. Loboda, A., Joziowicz, A. & Dulak, J. HIF-1 and HIF-2 transcription factors-similar not identical. Mol. Cells. 29, 435–442 (2010).
14. Shao, Y. et al. The landscape of interactions between hypoxia-inducible factors and reactive oxygen species in the gastrointestinal tract. Oxid. Med. Cell Longev. 1, 1–9 (2021).
15. Courtmey, R. et al. Cancer metabolism and the warburg effect the role of HIF-1 and PI3K. Mol. Biol. Rep. 42, 841–851 (2015).
16. Hao, L. et al. Correlation and expression analysis of hypoxia-inducible factor 1a, glucose transporter 1 and lactate dehydrogenase in human gastric cancer. Oncol. Lett. 18, 1431–1441 (2019).
17. Hao, Y., Baker, D. & Ten Dijke, P. TGF-α-mediated epithelial-mesenchymal transition and cancer metastasis. Int. J. Mol. Sci. 20, 2767 (2019).
18. Heikkonen, P. T. et al. Hypoxic conversion of SMAD7 function from an inhibitor into a promoter of cell. Cancer Res. 70, 3984–3993 (2010).
19. Sanchez-Elsner, T. et al. Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression. J. Biol. Chem. 276, 38527–38535 (2001).
20. Chen, X. & Xu, L. Mechanism and regulation of nucleocytoplasmic trafficking of Smad. Cell Biosci. 1, 40–48 (2011).
21. Pritchett, N. R. et al. Serum ghrelin and esophageal and gastric cancer in two cohorts in China. Int. J. Cancer. 146, 2728–2735 (2020).
22. Hu, X. L. et al. Ghrelin affects gastric cancer progression by activating AMPK signaling pathway. *Biochem. Genet.* **59**, 652–667 (2021).
23. Waseem, T. et al. Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. *Surgery.* **143**, 334–342 (2007).
24. Habara, H. et al. Organ-specific activation of the gastric branch of the efferent vagus nerve by ghrelin in urethane anesthetized rats. *J. Pharmacol. Sci.* **124**, 31–39 (2014).
25. Soleyman-Jahi, S. et al. Attribution of ghrelin to cancer; attempts to unravel an apparent controversy. *Front. Oncol.* **9**, 1–25 (2019).
26. Carling, D. AMPK signaling in health and disease. *Curr. Opin. Cell Biol.* **45**, 31–37 (2017).
27. Liberti, M. V. & Locasale, J. W. The Warburg effect: How does it benefit cancer cells?. *Trends Biochem. Sci.* **41**, 211–218 (2016).
28. Wu, S. et al. Aberrant expression of the long non-coding RNA GHRLOS and its prognostic significance in patients with colorectal cancer. *J. Cancer.* **8**, 4040–4047 (2017).
29. Al-Harithy, R. & Anbari, D. Downregulation of circulating long non-coding RNAs GHRLOS and LINC00852 associated with type 2 diabetes mellitus. *J. Dis. Mark.* **5**, 1038–1013 (2020).
30. Hong, L. et al. Linc-pint overexpression inhibits the growth of gastric tumors by downregulating HIF-1a. *Mol. Med. Rep.* **20**, 2875–2881 (2019).
31. Huang, R. et al. DZNep inhibits HIF-1a and Wnt signalling molecules to attenuate the proliferation and invasion of BGC-823 gastric cancer cells. *Oncol. Lett.* **18**, 4308–4316 (2019).
32. Muz, B., De la Puente, P. & Azab, A. K. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. *Hypoxia.* **3**, 83–92 (2015).
33. Chowdhury, R. et al. Nitric oxide produced endogenously is responsible for hypoxia-induced HIF-1a stabilization in colon carcinoma cells. *Chem. Res. Toxicol.* **25**, 2194–2202 (2012).
34. Kietzmann, T. & Gorlach, A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. *Sem. Cell Dev. Biol.* **16**, 474–486 (2005).
35. Han, S. U. et al. CEACAM5 and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling. *Oncogene* **27**, 675–683 (2008).
36. Kokkonen, N. et al. Hypoxia upregulates carcinoembryonic antigen expression in cancer cells. *Int. J. Cancer.* **12**, 2443–2450 (2007).
37. Li, S. et al. Chronic hypoxia elevates intracellular pH and activates Na+/H+ exchange in pulmonary arterial smooth muscle cells. *Am. J. Physiol. Lung Cell Mol. Physiol.* **289**, 867–874 (2005).
38. Koshiji, M. et al. HIF-1a induces cell cycle arrest by functionally counteracting Myc. *EMBO J.* **23**, 1949–1956 (2004).
39. Zizi-Sermpetzoglou, A. et al. A study of Smad4 and Smad7 expression in surgically resected samples of gastric adenocarcinoma and their correlation with clinicopathological parameters and patient survival. *J. BUON.* **19**, 221–227 (2014).
40. Jiang, X. et al. The correlation between NEDD4l and HIF-1α level as a gastric cancer prognostic marker. *I. J. Med. Sci.* **16**, 1517–1524 (2019).
41. McMahon, S. et al. Transforming growth factor β1 induces hypoxia-inducible factor-1 stabilization though selective inhibition of PHD2 expression. *J. Biol. Chem.* **281**, 24171–24181 (2006).
42. Ravil, F. M. et al. Ghrelin decreases angiogenesis, HIF-1a and VEGF protein levels in chronic hypoxia in lung tissue of male rats. *Adv. Pharm. Bull.* **5**, 315–320 (2015).
43. Barth, D. A. et al. Long non-coding RNA (IncRNA) in the regulation of hypoxia-inducible factor (HIF) in cancer. *Noncoding RNA.* **6**, 27–47 (2020).

**Author contributions**
N.A.H.: Formal analysis, Resources, Writing, Review, Editing. M.M.R. and A.S.A.: Supervision, Validation; Visualization. A.M.H.: samples collection. H.M.M.: Methodology, Resources.

**Funding**
Open access funding provided by The Science, Technology and Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

**Competing interests**
The authors declare no competing interests.

**Additional information**
Correspondence and requests for materials should be addressed to N.A.H.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022